About Kallyope
Kallyope is a company based in New York (United States) founded in 2014 by Charles Zuker, Richard Axel, and Tom Maniatis. Kallyope has raised $479 million across 6 funding rounds from investors including Illumina, ARE and StepStone Group. The company has 84 employees as of December 31, 2021. Kallyope offers products and services including Klarity Platform. Kallyope operates in a competitive market with competitors including Evelo Biosciences, Synlogic Therapeutics, Trace Genomics, PathogenDX and Manus Bio, among others.
- Headquarter New York, United States
- Employees 84 as on 31 Dec, 2021
- Founders Charles Zuker, Richard Axel, Tom Maniatis
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kallyope Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$479 M (USD)
in 6 rounds
-
Latest Funding Round
$8.2 M (USD), Grant
May 10, 2023
-
Investors
Illumina
& 20 more
-
Employee Count
84
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kallyope
Kallyope offers a comprehensive portfolio of products and services, including Klarity Platform.
Technology for discovering therapeutics in metabolic and neurological fields.
People of Kallyope
Unlock access to complete
Unlock access to complete
Funding Insights of Kallyope
Kallyope has successfully raised a total of $479M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $8.2 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kallyope
Kallyope has secured backing from 21 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Illumina, ARE and StepStone Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Early-stage investments in US life science startups are focused on.
|
Locked | Locked | Locked |
Investor details for Kallyope
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kallyope
Investment portfolio details for Kallyope
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kallyope
Detailed financials for Kallyope
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kallyope Comparisons
Peer comparison for Kallyope
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kallyope
Kallyope operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, Synlogic Therapeutics, Trace Genomics, PathogenDX and Manus Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| Locked | Locked | Locked |
Engineered microbes are developed as programmable therapeutics for metabolic disorders.
|
|
| Locked | Locked | Locked |
Developer of technologies to diagnose soil health and soil-borne disease prediction
|
|
| Locked | Locked | Locked |
Provider of DNA-based pathogen testing kits
|
|
| Locked | Locked | Locked |
Phytochemicals are developed using microbial fermentation processes.
|
Detailed competitors of Kallyope
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kallyope
Complete news archive for Kallyope
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kallyope
Kallyope was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Kallyope is headquartered in New York, United States. It is registered at New York, New York, United States.
Jay Galeota is the current CEO of Kallyope.
Kallyope is a funded company, having raised a total of $479M across 6 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Kallyope is 84.
Kallyope was founded in 2014 in New York, United States, as a biotechnology platform focused on the gut-brain axis. Technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics are integrated to study interactions between the brain and gut microbes. This approach is applied to identify microbiome-derived molecules that influence human behavior, leading to the development of therapeutics and nutritional products for health improvement.
Kallyope's top competitors include PathogenDX, Trace Genomics and Azitra.
Kallyope offers Klarity Platform.
Kallyope has 21 investors. Key investors include Illumina, ARE, StepStone Group, Gates Foundation, and Mubadala.